CSat Investment Advisory L.P. grew its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 63.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,660 shares of the company’s stock after acquiring an additional 4,138 shares during the period. CSat Investment Advisory L.P.’s holdings in Merck & Co., Inc. were worth $820,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of MRK. Sowa Financial Group Inc. acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $27,000. Total Clarity Wealth Management Inc. acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $27,000. Stephenson National Bank & Trust acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $28,000. Pacifica Partners Inc. acquired a new stake in shares of Merck & Co., Inc. in the 4th quarter valued at about $35,000. Finally, Lion Street Advisors LLC acquired a new stake in shares of Merck & Co., Inc. in the 1st quarter valued at about $35,000. Institutional investors own 74.23% of the company’s stock.

In related news, Director Wendell P. Weeks sold 5,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $76.02, for a total value of $380,100.00. Following the completion of the transaction, the director now directly owns 5,100 shares in the company, valued at approximately $387,702. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.28% of the stock is currently owned by insiders.

Several analysts have recently commented on MRK shares. Credit Suisse Group restated a “buy” rating and issued a $95.00 target price on shares of Merck & Co., Inc. in a research note on Monday, May 4th. SVB Leerink reduced their target price on Merck & Co., Inc. from $98.00 to $95.00 and set an “outperform” rating for the company in a research note on Wednesday, April 29th. Barclays dropped their price target on shares of Merck & Co., Inc. from $93.00 to $90.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 29th. ValuEngine raised shares of Merck & Co., Inc. from a “sell” rating to a “hold” rating in a research report on Saturday, February 29th. Finally, UBS Group dropped their target price on shares of Merck & Co., Inc. from $96.00 to $92.00 and set a “buy” rating on the stock in a research report on Monday, April 13th. Three analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Merck & Co., Inc. currently has a consensus rating of “Buy” and a consensus price target of $94.21.

Shares of NYSE:MRK traded up $0.19 during mid-day trading on Friday, reaching $79.24. The company had a trading volume of 4,006,405 shares, compared to its average volume of 9,761,534. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 0.82. The firm has a market cap of $195.74 billion, a price-to-earnings ratio of 19.97, a PEG ratio of 2.15 and a beta of 0.50. The company’s 50-day moving average price is $79.52 and its 200-day moving average price is $83.13. Merck & Co., Inc. has a one year low of $65.25 and a one year high of $92.64.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, April 28th. The company reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.16. The company had revenue of $12.06 billion for the quarter, compared to analysts’ expectations of $11.46 billion. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 52.46%. Merck & Co., Inc.’s revenue was up 11.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.22 EPS. On average, research analysts anticipate that Merck & Co., Inc. will post 5.31 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 7th. Investors of record on Monday, June 15th will be paid a $0.61 dividend. The ex-dividend date is Friday, June 12th. This represents a $2.44 dividend on an annualized basis and a yield of 3.08%. Merck & Co., Inc.’s dividend payout ratio is 47.01%.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Recommended Story: What is the QQQ ETF?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.